Thus, although more data should be gathered to support the use of AURKA inhibitors in primary tumours, where AR overexpression is not common, existing AURKA inhibitors could be useful in treating CRPC patients overexpressing full-length AR with or without AR-Vs, a finding that should be tested in future clinical trials. This evidence concerns the gene AR and neoplasm.